Allogene’s ALLO-501 Shows Positive Results in Its Phase I ALPHA Trial

Today, San Francisco-based biotech company Allogene Therapeutics announced results for its ALLO-501 Phase 1 ALPHA study, along with its development partner, Servier. The data, which was presented at the American Society of Clinical Oncology annual meeting, looked into the use of ALLO-501 for relapsed/refractory non-Hodgkin lymphoma.